McClellan William D. Jr. 4
4 · REATA PHARMACEUTICALS INC · Filed Aug 1, 2023
Insider Transaction Report
Form 4
McClellan William D. Jr.
Director
Transactions
- Conversion
Class B common stock
2023-07-28−5,000→ 0 total→ Class A common stock (5,000 underlying) - Conversion
Class A common stock
2023-07-28+5,000→ 11,017 total - Exercise/Conversion
Stock Option (right to buy)
2023-07-28−5,000→ 4,500 totalExercise: $26.46Exp: 2027-03-01→ Class B common stock (5,000 underlying) - Exercise/Conversion
Class B common stock
2023-07-28$26.46/sh+5,000$132,300→ 5,000 total→ Class A common stock (5,000 underlying) - Sale
Class A common stock
2023-07-28$164.49/sh−5,000$822,442→ 6,017 total
Footnotes (4)
- [F1]The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- [F2]The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $164.69. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The options vested in three equal installments on March 1, 2018, March 1, 2019 and March 1, 2020.